Vaccine Trial for Newborns in Guinea-Bissau Halted Amid Ethical Concerns
A US-funded hepatitis B vaccine trial for newborns in Guinea-Bissau has been halted due to lack of government approval and ethical concerns.
A vaccine trial in Guinea-Bissau intended for newborns has been officially halted after lead researcher Frederik Schaltz-Buchholzer announced that the study would not proceed without necessary governmental approval. The halt follows significant backlash from global health experts who criticized the ethical implications of the trial, which aimed to randomly assign over 14,000 newborns to receive or not receive the hepatitis B vaccine.
The study was set to be funded by a combined $3.2 million from the US Centers for Disease Control and Prevention (CDC) and private partners such as the Pershing Square Foundation. However, Quinhin Nantote, the Minister of Health in Guinea-Bissau, confirmed that the government had not authorized the project, categorically denying progress on it. “This is not even remotely true,” Nantote stated, rejecting claims that the trial had begun.
On Monday, police raided the offices of the Bandim Health Project, where the trial was based, confiscating vaccines earmarked for the study. The police stated that the operation was part of an ongoing investigation to clarify the circumstances surrounding the vaccines but emphasized that the seizure did not imply any irregularities regarding their quality or safety.
Experts, including vaccine specialist Paul Offit, condemned the trial as unethical, arguing that the design forced participants into a coercive situation regarding informed consent. He noted that denying parents the option to vaccinate their newborns outside the trial created a significant ethical dilemma.
The controversy surrounding the trial intensified following claims that it resembled historical ethical violations, such as the Tuskegee experiment. Critics alleged that the testing of vaccines in African populations, particularly those already shown to be safe and effective, raises ethical red flags.
In a LinkedIn post, Schaltz-Buchholzer noted the trial’s cancellation, stating unequivocally that it was now clear it would not move forward due to a lack of government approval. He indicated that the work aimed to investigate the mortality effects and potential side effects of the vaccine mix, although this faced skepticism.
The World Health Organization (WHO) maintains a strong stance on immunizing all newborns against hepatitis B, advocating for the birth dose to be administered within 24 hours of birth. WHO officials have expressed concern over the high prevalence of hepatitis B in Guinea-Bissau, where over 12% of adults and approximately 2% of children under five are infected.
The CDC and the Danish researchers involved have not provided updates regarding potential changes in funding or the direction of future vaccine distribution in light of this halted trial. WHO spokesperson Tarik Jašarević reiterated the importance of timely vaccination for newborns globally.
